Velorum Therapeutics
YC W24San Francisco, US · Founded 2023 · 5 employees · 6 known investors
Velorium develops transformational medicines by combining scientific research with patient-focused collaboration. The company operates in the medical research and therapeutic development space.
BiotechHealthtechMedical DevicesHealthcareTherapeuticsDrug discoveryOncologyUnited States of AmericaAmerica / Canada
Founders & leadership· Y Combinator alumni (W24)
Velorum Therapeutics was founded in 2023 by Pouya Modareszadeh and Parsa Modareszadeh.
PM
Pouya Modareszadehin𝕏Co-Founder & CEOPouya Modareszadeh is co-founder and CEO of Velorum Therapeutics, a company developing therapeutic medicines.
PM
Parsa Modareszadehin𝕏Co-Founder & PresidentParsa Modareszadeh is co-founder and president of Velorum Therapeutics, where he works on drug development. He was a Goldwater Scholar.
Investors · 6
Competitors · 6
by search overlapEpirium8 shared keywordsEpirium Bio develops novel oral therapeutics targeting mitochondrial dysfunction and muscle diseases, particularly muscular dystrophy. The company's lead compound, EPM-01, is in Phase 1 clinical development for Becker muscular dystrophy.
Alterome Therapeutics, Inc.8 shared keywordsAlterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic. It focuses on hard-to-drug cancer targets such as mutant KRAS and mutant AKT E17K across malignancies including non-small cell lung, pancreatic, colorectal, endometrial, and breast cancers.
Orum Therapeutics Venture Capital8 shared keywordsOrum is a global biopharmaceutical company developing cancer therapies that combine protein degraders with antibodies. It focuses on Degrader Antibody Conjugate (DAC) technology to research and develop new therapeutics.
Adverum7 shared keywordsAdverum is a clinical-stage gene therapy company developing Ixo-vec, an investigational single-administration intravitreal treatment for wet age-related macular degeneration and other ocular diseases, based on a proprietary adeno-associated virus (AAV) vector platform. Its therapies aim to transform retinal cells into biofactories that continually produce anti-VEGF protein, reducing the need for frequent eye injections.
Mirum Pharmaceuticals6 shared keywordsMirum Pharmaceuticals is a biopharmaceutical company that develops and delivers therapies for people living with rare diseases. It operates in the U.S. and Europe, engaging with healthcare professionals, patients, and payers within applicable regulatory frameworks.
Bioworld6 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Velorum Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Velorum Therapeutics do?
- Velorium develops transformational medicines by combining scientific research with patient-focused collaboration. The company operates in the medical research and therapeutic development space.
- Who founded Velorum Therapeutics?
- Velorum Therapeutics was founded by Pouya Modareszadeh, Parsa Modareszadeh in 2023.
- Who are Velorum Therapeutics's investors?
- Velorum Therapeutics's investors include Metaplanet, MyAsiaVC, SciFounders, Y Combinator, 468 Capital, Ritual Capital.
- Where is Velorum Therapeutics headquartered?
- Velorum Therapeutics is headquartered in San Francisco, US.